Continuous glucose monitoring (CGM) systems

Introduction and Mechanism of Action

• Continuous glucose monitoring (CGM) systems have revolutionized the management of type 1 and type 2 diabetes mellitus by providing real-time, dynamic information regarding glycemic excursions.
• The system typically utilizes a small, transcutaneous sensor inserted into the subcutaneous tissue to measure interstitial fluid glucose concentrations using glucose-oxidase–based electrochemical methods.
• CGM devices report glucose concentrations approximately every 5 minutes, yielding up to 288 readings per 24-hour period.
• In addition to providing near-current glucose values, these systems provide critical rate-of-change trend arrows and predictive alarms for impending hypoglycemia or severe hyperglycemia.
• Data from the CGM sensor is transmitted to a receiver, which can be a dedicated device or integrated with smartphones, tablets, or smartwatches, allowing for remote monitoring by parents, caregivers, or healthcare providers via cloud-based systems.
• The use of CGM generates massive amounts of glycemic data, shifting the paradigm of metabolic monitoring from traditional hemoglobin A1c (HbA1c) toward digital biomarkers such as Time in Range (TIR), Time Below Range (TBR), and Time Above Range (TAR).
• The universally accepted clinical target for Time in Range is defined as a sensor glucose concentration between 70 and 180 mg/dL (3.9 to 10 mmol/L).
• To contextualize these targets, physiological CGM data in healthy children aged 2 to 8 years demonstrate that sensor glucose levels remain almost entirely between 72 and 140 mg/dL, with a highly stable glycemic pattern characterized by a mean glucose standard deviation of 1.0 mmol/L and a coefficient of variation of 18.87%.

Types of Continuous Glucose Monitoring Systems

• Retrospective or Blinded CGM: These devices collect continuous glucose data without displaying it to the patient in real time. They are primarily utilized by healthcare providers over a short duration to identify occult glycemic patterns, assist with complex diagnoses (such as cystic fibrosis-related diabetes), and guide targeted insulin adjustments.
• Real-Time CGM (rtCGM): These systems continuously display the interstitial glucose concentration to the user, accompanied by trend arrows and customizable real-time alarms for predetermined high and low glucose thresholds.
• Intermittently Scanned CGM (isCGM / Flash Glucose Monitoring): Unlike rtCGM, these systems do not constantly display glucose readings or provide automatic alarms. Instead, the user must actively hold a reader or a compatible smartphone close to the sensor to retrieve the current glucose level and the retrospective data curve.
• Implantable Sensors: A newer class of long-term implantable subcutaneous real-time sensors has been approved for up to 3 to 6 months of continuous wear, offering an alternative to standard transcutaneous sensors that typically require replacement every 6 to 14 days.

Accuracy and Nonadjunctive Use

• Historically, CGM systems required frequent calibration via capillary self-monitoring of blood glucose (SMBG) using traditional fingersticks.
• Current technological advancements have produced factory-calibrated CGM and isCGM systems that completely eliminate the need for routine SMBG calibration.
• The clinical standard for sensor accuracy is defined by the mean absolute relative difference (MARD); a growing number of modern sensors achieve a MARD of less than 10%.
• A MARD of less than 10% across all glucose ranges permits the "nonadjunctive" use of CGM, meaning patients and clinicians can safely calculate and adjust insulin boluses based solely on sensor data without requiring a confirmatory capillary fingerstick.
• Nonadjunctive use is considered most reliable when the patient is not actively hypoglycemic and the sensor glucose is not changing rapidly.

Clinical Evidence and Efficacy

• Extensive randomized controlled trials (RCTs) and real-world registry data confirm that CGM use significantly lowers HbA1c levels, decreases overall glycemic variability, and reduces the time spent in hypoglycemia.
• The clinical benefits of CGM are highly dependent on the frequency of sensor wear; maximal benefits are consistently demonstrated when the sensor is utilized near-continuously, defined as greater than 6 days per week.
• While initial evidence was strongest in adult and adolescent populations, recent data conclusively demonstrate significant metabolic benefits in preschool children and toddlers, particularly when analysis is strictly focused on the periods of active sensor use.
• CGM is highly effective in detecting asymptomatic nocturnal hypoglycemia, allowing for the lowering of HbA1c targets without concomitantly increasing the risk for severe hypoglycemic events.

Integration with Insulin Pumps: Sensor-Augmented Therapy

• Sensor-Augmented Pump (SAP) Therapy: This involves linking a real-time CGM directly to an insulin pump via a control algorithm, representing a significant technological step toward an artificial pancreas. SAP has been proven superior to multiple daily injections (MDI) with SMBG, yielding significant decreases in HbA1c and glycemic variability.
• Low Glucose Suspend (LGS): The next evolution in SAP therapy incorporates an automated LGS modality. This algorithm automatically suspends the pump's basal insulin delivery for up to 2 hours if the patient's sensor glucose falls below a predetermined threshold and the patient fails to respond to alarms. RCTs demonstrate that LGS significantly reduces the duration and severity of nocturnal hypoglycemia without elevating overall HbA1c or blood beta-hydroxybutyrate (BOHB) levels.
• Predictive Low Glucose Suspend (PLGS): This advanced modality utilizes predictive algorithms to interrupt basal insulin delivery before hypoglycemia even occurs. The system suspends insulin when the sensor trend predicts the glucose will reach the hypoglycemic limit within 30 minutes, and it automatically resumes insulin delivery once normoglycemia is restored. PLGS drastically reduces hypoglycemic exposure and the occurrence of severe hypoglycemic events.
• Hybrid Closed-Loop Systems (Artificial Pancreas): The current pinnacle of CGM integration utilizes proportional integrative derivative, model predictive control, or fuzzy logic algorithms to automatically and continuously regulate basal insulin infusion rates every 5 minutes based on CGM input. These systems operate in a "hybrid" mode because the patient must still manually announce meals and deliver premeal carbohydrate boluses. They have been proven to significantly increase Time in Range and reduce both nocturnal hypoglycemia and exercise-induced hypoglycemia.

Practical Considerations and Challenges

• The successful implementation of CGM requires rigorous, structured education and the setting of realistic expectations for the patient, family, and school personnel.
• Individualized and sensible alarm configurations are paramount; overly sensitive or broad alarms frequently induce "alarm fatigue" and psychological burden, which is a leading cause of device attrition and non-adherence.
• Inadequate sensor adhesiveness and localized skin irritation (contact dermatitis) are substantial barriers to long-term CGM use, particularly in young children and infants whose available body surface area is limited.
• Management of skin issues requires regular insertion site rotation, the judicious use of adhesive removers to prevent epidermal trauma, and the application of supplementary barrier products, liquid adhesives, and transparent dressings (e.g., IV-3000, Tegaderm).
• Despite technological safeguards like PLGS, patients and caregivers must be thoroughly educated to remain alert to systems alarms, properly administer rescue carbohydrates for breakthrough hypoglycemia, and actively monitor for infusion set failures that could precipitate diabetic ketoacidosis.